The aim of this study was to characterize the presence of carbapenemase-encoding genes in distinct species of Acinetobacter spp. isolated from Brazilian hospitals. Five carbapenem-resistant Acinetobacter spp. isolates (two Acinetobacter pittii, two Acinetobacter bereziniae and one Acinetobacter junii) recovered from two distinct hospitals between 2000 and 2016 were included in this study. All of the isolates harboured bla IMP-1 , which was inserted into In86, a class 1 integron. Pulsed field gel eletrophoresis analysis showed that both A. pittii were identical, while the two A. berezinae isolates were considered to be clonally related. In this study, we demonstrated that mobile elements carrying carbapenemase-encoding genes such as In86 may persist for a long period, allowing their mobilization from A. baumannii to other Acinetobacter spp. that are usually susceptible to multiple antimicrobials.
In recent years, carbapenem resistance in Acinetobacter species has mainly been reported in Acinetobacter baumannii. However, other Acinetobacter species have emerged as important nosocomial pathogens and, in some cases, they present high levels of antimicrobial resistance [1] . The real prevalence of carbapenem resistance in non-baumannii species might be underestimated because of the inability of phenotypic tests to accurately identify Acinetobacter at the species level [2] . rpoB gene sequence analysis has been considered to be the gold standard methodology for species identification [2] . Carbapenem resistance in Acinetobacter spp. has mainly been attributed to the production of carbapenem-hydrolyzing class D b-lactamases [1, 3] . Here we reported the occurrence of three non-baumannii species carrying bla IMP-1 , a metallo-b-lactamase-encoding gene, isolated from two Brazilian hospitals.
As part of a routine surveillance, only six non-baumannii Acinetobacter spp. were isolated that were resistant to carbapenems. Five of these isolates remained viable and were further characterized. These isolates were collected from the blood (n=3) and tracheal aspirate (n=2) of five distinct patients hospitalized in two tertiary hospitals located in the city of São Paulo, Brazil between 2000 and 2016 (Table 1) . These isolates had originally identified as Acinetobacter spp. (A3146 and A4258) and Acinetobacter lwoffii (A64232, A67461 and A69575) by automated systems. rpoB gene sequencing [2] later identified the isolates as Acinetobacter pittii (n=2), Acinetobacter bereziniae (n=2) and Acinetobacter junii (n=1). Minimal inhibitory concentrations (MICs) were determined and interpreted by broth microdilution according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) recommendations (http://www.eucast.org/clinical_breakpoints/), as shown in Table 1 . All of the isolates showed high MICs for third-and fourth-generation cephalosporins (MICs >64 mg l The presence of carbapenemase-encoding genes was confirmed by PCR followed by sequencing using specific primers [3, 4] , and demonstrated that all strains carried the bla IMP-1 gene. To elucidate the genetic context of bla IMP-1 , DNA amplification and sequencing were performed as previously described [3] , and revealed that this gene was inserted into a class 1 integron, In86, that also carried two aminoglycoside-modifying enzymes encoding the genes aacA31 and aadA1a. The clonal relatedness of the two A. pittii isolates, as well as the two A. bereziniae isolates, was evaluated by pulsed field gel eletrophoresis (PFGE) using the ApaI restriction enzyme [3] . PFGE analysis showed that the A. pittii isolates were identical, while the two A. bereziniae isolates were clonally related.
Since its first description in Serratia marcescens isolated in Japan, bla IMP-1 has been reported in several Gram-negative rods [4] . Although IMP-1 has become endemic in eastern Asia, it has been sporadically reported in non-baumannii Acinetobacter species in that region [1] , as well as in Europe and South America, where IMP variants are more commonly reported in A. baumannii [3, 5] . IMP-1-producing A. baumannii were initially detected in our institution in 1998, and since then the frequency of this micro-organism has increased [5] . The class 1 integron In86 has been described in different Gram-negative bacilli among distinct hospitals located in the state of São Paulo [4] . The two IMP-1-producing A. pittii isolates were recovered in our institution in the early 2000s, and had probably acquired this resistant determinant from A. baumannii. Interestingly, we previously reported two A. baumannii isolates recovered in hospital A that harboured a new plasmidmediated class 1 integron named In990, which was derived from In86 and carried bla IMP-10 . This suggests that this genetic element has also undergone an evolution, probably due to selective pressure exerted by the local use of antimicrobials [3] . Park and colleagues also identified bla IMP-1 in A. pittii and A. bereziniae in South Korea, highlighting the spread of this resistance gene among non-baumannii species of Acinetobacter [6] . In addition, the presence of bla IMP-1 in two A. bereziniae isolates and an A. junii, more than 13 years apart and in a different hospital, emphasizes the persistence and spread of bla IMP-1 -borne In86 over the years.
Although A. non-baumannii isolates are usually susceptible to many antimicrobial agents [1] , additional caution should be taken due to the possibility of the acquisition of mobile genetic elements carrying resistance genes, as exemplified in this report. Our results emphasize the need for the proper implementation of infection control measures and accurate species identification in order to avoid patient-to-patient Table 1 . Conflicts of interest A. C. G. recently received research funding and/or consultation fees from BD, Bayer, Pfizer and MSD. The other authors have nothing to declare. This study has not been financially supported by any diagnostic/pharmaceutical company.
